In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Valocor Therapeutics Inc.

Division of Dermira Inc.
www.valocor.com

Latest From Valocor Therapeutics Inc.

Financings Of The Fortnight: Corporate Venture Contributing In A Big Way

Once an unlikely scenario, corporate venture funds now are making up a larger and larger part of investment rounds for early-stage biotechs; these investments are buoyed by VCs launching their own firms. Plus news on recent financing activity from Avaxia Biologics, Clovis Oncology, Protagonist Therapeutics and Dermira.

BioPharmaceutical North America

Start-Up Quarterly Statistics, Q4 2011

Biopharma start-ups raised $693 million in Q4 2011, up 131% from Q3. Device companies brought in $111 million, and diagnostics firms raised $120 million total, $96 million of which was from Biocartis’ Series C. Cancer was the most prevalent therapeutic area for biopharma alliances. And in great contrast to Q3’s one M&A deal involving a start-up company, Q4 saw nine start-up acquisitions.

BioPharmaceutical Medical Device

Start-Up Quarterly Statistics, Q2 2010

Highlights from the Q2 2010 review of start-up dealmaking: Biopharma, medical device and in vitro diagnostics startups raised a total of $606 million, an 83% hike from the previous quarter but a 30% drop from Q2 2009. Unlike Q1, which saw four spin-offs, Q2 had just one. Three acquisitions closed including J&J's purchase of respiratory-focused RespiVert. During the second quarter of 2010, several companies signed multiple agreements including Clovis Oncology.
BioPharmaceutical Medical Device

Deals Shaping the Medical Industry (07/2010)

The dealmaking column is a survey of recent transactions, including strategic alliances, mergers & acquisitions, and financings, in the life sciences industries. Deals are listed by the following industry sectors: in vitro diagnostics, pharmaceuticals, medical devices, and research/analytical instrumentation and reagents. All transactions are excerpted from Elsevier's Strategic Transactions database, providing comprehensive transaction coverage from 1991 to the present.
See All

Company Information

  • Industry
  • Biotechnology
  • Pharmaceuticals
  • Therapeutic Areas
  • Dermatology
  • Inflammation
  • Alias(es)
  • Ownership
  • Private
  • Headquarters
  • Worldwide
    • North America
      • Canada
  • Parent & Subsidiaries
  • Dermira Inc.
  • Senior Management
  • Daniel Wattier, Pres. & CEO
    David Hunt, VP, Research
  • Contact Info
  • Valocor Therapeutics Inc.
    777 Dunsmuir St.
    Ste. 1300
    Vancouver,
    Canada
Advertisement
Advertisement
UsernamePublicRestriction

Register